Trending...
- Anne Litz to Serve as Executive Director of Maryland Horse Industry Board
- Beya Premium Ai Track: Pioneering Ai Innovation Across Industries
- Maryland: State Soil Conservation Committee Meeting Notice
NEW YORK, May 7, 2024 ~ Myrtelle Inc., a clinical-stage gene therapy company, will be hosting a symposium at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting on Wednesday, May 8, 2023. The symposium will focus on Canavan disease (CD) clinical trial updates and future directions for oligodendrocyte targeting AAVs.
Canavan disease is a fatal childhood genetic brain disease caused by mutations in the ASPA gene. This prevents the normal expression of aspartoacylase, a critical enzyme produced in oligodendrocytes. These cells play a crucial role in brain function by producing myelin, the insulating material that enables proper neuronal function.
The symposium will feature speakers such as Paola Leone, Ph.D., Professor and Director of the Cell and Gene Therapy Center at Rowan-Virtua SOM & School of Translational Biomedical Engineering & Sciences Virtua Health College of Medicine and Life Sciences of Rowan University. She will discuss the history of her work in Canavan disease and the development of a gene therapy targeting oligodendrocytes.
More on Marylandian
Rob Lober, M.D., Ph.D., Principal Investigator on Myrtelle's Canavan Disease Gene Therapy Trial and Attending Neurosurgeon at Dayton Children's Hospital and Associate Professor of Pediatrics at Wright State University Boonshoft School of Medicine, will present a case study from Myrtelle's Phase 1/2 First-in-Human Gene Therapy Clinical Trial in Patients with Canavan Disease. His talk is titled "Oligodendrocyte Targeted Gene Therapy for Canavan Disease."
Patrick Aldrin-Kirk, Ph.D., Chief Science Officer at rAAVen, an AAV engineering company focused on generating innovative vectors for gene therapies, will also be presenting. He will discuss the discovery of novel oligodendrocyte targeting AAV capsids and potential disease targets.
Jordana Holovach, Head of Communications and Community at Myrtelle, expressed excitement about the symposium, stating that it provides a unique opportunity to highlight the critical role of oligodendrocytes in brain health and their potential as a target for treating neurodegenerative diseases. She also mentioned the company's evolving toolbox for delivering therapeutic constructs to these cells and its potential impact on previously untreatable diseases.
More on Marylandian
The symposium will take place at the Baltimore Convention Center in Room 324-326 from 8:30 am to 9:30 am. Myrtelle Inc. is a gene therapy company focused on developing treatments for neurodegenerative diseases. The company has a proprietary platform, intellectual property, and portfolio of programs and technologies supporting innovative gene therapy approaches.
Myrtelle has an exclusive worldwide licensing agreement with Pfizer Inc. for its Canavan disease program. More information on Myrtelle's clinical trial in Canavan disease can be found on https://clinicaltrials.gov/ under the identifier NCT04833907 or by emailing [insert email address]. For more information about Myrtelle, please visit their website at www.myrtellegtx.com.
Canavan disease is a fatal childhood genetic brain disease caused by mutations in the ASPA gene. This prevents the normal expression of aspartoacylase, a critical enzyme produced in oligodendrocytes. These cells play a crucial role in brain function by producing myelin, the insulating material that enables proper neuronal function.
The symposium will feature speakers such as Paola Leone, Ph.D., Professor and Director of the Cell and Gene Therapy Center at Rowan-Virtua SOM & School of Translational Biomedical Engineering & Sciences Virtua Health College of Medicine and Life Sciences of Rowan University. She will discuss the history of her work in Canavan disease and the development of a gene therapy targeting oligodendrocytes.
More on Marylandian
- Solas Brings Their 30th Anniversary Tour to the Weinberg Center
- New Jersey Sober Living Opens New Luxury Themed Facility in South New Jersey
- Hawaii Bill Marks Progress in Protecting Patients From Dangerous Restraint Practices
- All me - secure anonymous social - kickstarter crowdfunding
- HomeFortis Launches Target Hardening Guides for Home Security
Rob Lober, M.D., Ph.D., Principal Investigator on Myrtelle's Canavan Disease Gene Therapy Trial and Attending Neurosurgeon at Dayton Children's Hospital and Associate Professor of Pediatrics at Wright State University Boonshoft School of Medicine, will present a case study from Myrtelle's Phase 1/2 First-in-Human Gene Therapy Clinical Trial in Patients with Canavan Disease. His talk is titled "Oligodendrocyte Targeted Gene Therapy for Canavan Disease."
Patrick Aldrin-Kirk, Ph.D., Chief Science Officer at rAAVen, an AAV engineering company focused on generating innovative vectors for gene therapies, will also be presenting. He will discuss the discovery of novel oligodendrocyte targeting AAV capsids and potential disease targets.
Jordana Holovach, Head of Communications and Community at Myrtelle, expressed excitement about the symposium, stating that it provides a unique opportunity to highlight the critical role of oligodendrocytes in brain health and their potential as a target for treating neurodegenerative diseases. She also mentioned the company's evolving toolbox for delivering therapeutic constructs to these cells and its potential impact on previously untreatable diseases.
More on Marylandian
- Retired Leadership Facilitator Shares Decades of Wisdom in New Book
- CCG Relaunches Spring Virtual Recruitment Fair to Connect Employers with Top STEM, AI, and Veteran Talen
- I belong (t)here, an exhibition that explores the fluidity of identity and the search for belonging in a world that is constantly shifting
- Js Art Gallery: A New International Art Space Promoting Unity Through Art
- Maryland: PHOTO RELEASE: Governor Moore Inducts Deford Family into Governor's Agriculture Hall of Fame
The symposium will take place at the Baltimore Convention Center in Room 324-326 from 8:30 am to 9:30 am. Myrtelle Inc. is a gene therapy company focused on developing treatments for neurodegenerative diseases. The company has a proprietary platform, intellectual property, and portfolio of programs and technologies supporting innovative gene therapy approaches.
Myrtelle has an exclusive worldwide licensing agreement with Pfizer Inc. for its Canavan disease program. More information on Myrtelle's clinical trial in Canavan disease can be found on https://clinicaltrials.gov/ under the identifier NCT04833907 or by emailing [insert email address]. For more information about Myrtelle, please visit their website at www.myrtellegtx.com.
Filed Under: Business
0 Comments
Latest on Marylandian
- Kelvin Emtech and Colm Engineering Unveil Strategic Joint Venture, to Boost Data Center and Building M&E Capabilities
- Citizens for West Virginia Election Integrity Calls for Urgent Reforms to Safeguard State Elections
- Patton Launches SFP-based RS-232/422/485 Serial Device Server
- Local Tech Entrepreneur Partners with WonderSouq To Offer Downtown Medford Businesses a Virtual City Experience
- Boston Bridal Atelier Enhances Luxury Experience with New Bridal Shop Location
- New Website for Solo Agers Over 50
- Malcolm-Jamal Warner Returns to Columbia for an Unforgettable Evening of Poetry & Music
- Slightly Stoopid, Damian & Stephen Marley to headline Everwild Music Festival in 2025
- Parkbench13 Media Group Inc. Seeks Artists for Sync Licensing Opportunities
- The Elevated Table Project Revolutionizes Cannabis-Infused Cooking & Cocktails
- THSYU Opens New Doors for Accredited Investors, Bridging the Gap Between Traditional Finance and the Digital Asset Frontier
- Latest DivX 11 Software Advances Video Playback, Conversion, and Streaming
- Gold Coast Health Plan Among State's Top Performers for Outstanding Health Care Quality
- Delaplaine Foundation Awards Weinberg Center Grant to Benefit Local Veterans
- NC Health Official Urges Ban on Wilderness Therapy Camps Following Child's Death
- Breaking Barriers & Elevating Voices: The Top 50 Over 50 Podcast Awards Set to Make History!
- Maryland: Preliminary Testing Confirms Highly Pathogenic Avian Influenza in Worcester County
- Maryland: Department Launches Farmer Outreach Campaign to Promote Tree Planting and Agroforestry Incentives
- The Power Of Online Reviews & Why They Matter
- Connected Technologies Delivers Cutting-Edge Technology to Landmark Properties' Student Housing Communities